346 related articles for article (PubMed ID: 28634480)
1. Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity.
Peschke B; Keller CW; Weber P; Quast I; Lünemann JD
Front Immunol; 2017; 8():646. PubMed ID: 28634480
[TBL] [Abstract][Full Text] [Related]
2. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
3. IgG subclasses and allotypes: from structure to effector functions.
Vidarsson G; Dekkers G; Rispens T
Front Immunol; 2014; 5():520. PubMed ID: 25368619
[TBL] [Abstract][Full Text] [Related]
4. Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.
Dekkers G; Treffers L; Plomp R; Bentlage AEH; de Boer M; Koeleman CAM; Lissenberg-Thunnissen SN; Visser R; Brouwer M; Mok JY; Matlung H; van den Berg TK; van Esch WJE; Kuijpers TW; Wouters D; Rispens T; Wuhrer M; Vidarsson G
Front Immunol; 2017; 8():877. PubMed ID: 28824618
[TBL] [Abstract][Full Text] [Related]
5. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
6. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
[TBL] [Abstract][Full Text] [Related]
7. Fc Galactosylation Promotes Hexamerization of Human IgG1, Leading to Enhanced Classical Complement Activation.
van Osch TLJ; Nouta J; Derksen NIL; van Mierlo G; van der Schoot CE; Wuhrer M; Rispens T; Vidarsson G
J Immunol; 2021 Sep; 207(6):1545-1554. PubMed ID: 34408013
[TBL] [Abstract][Full Text] [Related]
8. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
9. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.
Thommesen JE; Michaelsen TE; Løset GÅ; Sandlie I; Brekke OH
Mol Immunol; 2000 Nov; 37(16):995-1004. PubMed ID: 11395138
[TBL] [Abstract][Full Text] [Related]
10. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
Front Immunol; 2018; 9():958. PubMed ID: 29867943
[TBL] [Abstract][Full Text] [Related]
11. IgG antibodies to cyclic citrullinated peptides exhibit profiles specific in terms of IgG subclasses, Fc-glycans and a fab-Peptide sequence.
Lundström SL; Fernandes-Cerqueira C; Ytterberg AJ; Ossipova E; Hensvold AH; Jakobsson PJ; Malmström V; Catrina AI; Klareskog L; Lundberg K; Zubarev RA
PLoS One; 2014; 9(11):e113924. PubMed ID: 25426976
[TBL] [Abstract][Full Text] [Related]
12. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells.
Hills AE; Patel A; Boyd P; James DC
Biotechnol Bioeng; 2001 Oct; 75(2):239-51. PubMed ID: 11536148
[TBL] [Abstract][Full Text] [Related]
13. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
14. Characterization of antibody-C1q interactions by Biolayer Interferometry.
Zhou W; Lin S; Chen R; Liu J; Li Y
Anal Biochem; 2018 May; 549():143-148. PubMed ID: 29577875
[TBL] [Abstract][Full Text] [Related]
15. Structural characterization of the Man5 glycoform of human IgG3 Fc.
Shah IS; Lovell S; Mehzabeen N; Battaile KP; Tolbert TJ
Mol Immunol; 2017 Dec; 92():28-37. PubMed ID: 29031045
[TBL] [Abstract][Full Text] [Related]
16. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.
Bindon CI; Hale G; Brüggemann M; Waldmann H
J Exp Med; 1988 Jul; 168(1):127-42. PubMed ID: 3260935
[TBL] [Abstract][Full Text] [Related]
17. Effects of weak/non-complement-binding HLA antibodies on C1q-binding.
Hönger G; Amico P; Arnold ML; Spriewald BM; Schaub S
HLA; 2017 Aug; 90(2):88-94. PubMed ID: 28585289
[TBL] [Abstract][Full Text] [Related]
18. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
19. Development of C1q Affinity Chromatography for the Study of C1q-IgG Interactions.
Marshall MJE; Knaupp A; Spick C; Koese I; Maier M; Cragg MS; Cymer F; Schlothauer T
J Immunol; 2023 Jun; 210(11):1837-1848. PubMed ID: 37093649
[TBL] [Abstract][Full Text] [Related]
20. Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation.
Wei B; Gao X; Cadang L; Izadi S; Liu P; Zhang HM; Hecht E; Shim J; Magill G; Pabon JR; Dai L; Phung W; Lin E; Wang C; Whang K; Sanchez S; Oropeza J; Camperi J; Zhang J; Sandoval W; Zhang YT; Jiang G
MAbs; 2021; 13(1):1893427. PubMed ID: 33682619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
